Sunshine Biopharma (SBFM) Revenue (2015 - 2026)

Sunshine Biopharma's Revenue history runs 10 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• Quarterly Revenue fell 9.13% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.5 million (down 2.05% YoY) and the FY2025 annual result came in at $36.3 million, up 4.11% from the prior year.
• Revenue was $8.1 million for Q1 2026 at Sunshine Biopharma, down from $8.6 million in the prior quarter.
• Across five years, Revenue topped out at $9.6 million in Q4 2024 and bottomed at $122645.0 in Q1 2022.
• A 5-year average of $6.3 million and a median of $7.7 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue jumped 4528.68% — and 2025, when it fell 10.61%.
• Sunshine Biopharma's Revenue stood at $3.9 million in 2022, then surged by 94.94% to $7.7 million in 2023, then advanced by 24.93% to $9.6 million in 2024, then decreased by 10.61% to $8.6 million in 2025, then decreased by 5.69% to $8.1 million in 2026.
• Business Quant data shows SBFM's Revenue at $8.1 million in Q1 2026, $8.6 million in Q4 2025, and $9.4 million in Q3 2025.